Resolutions from the annual general meeting of CombiGene AB, 29 June 2020

Jun 29, 2020

Today, on 29 June 2020, CombiGene AB held its annual general meeting (“AGM”) in Lund. The AGM elected Filip Funk, lawyer at Fredersen Advokatbyrå, as the chairman of the meeting and keeper of the minutes. The AGM resolved on all matters in accordance with previously published proposed resolutions by the board of directors or the nomination committee. A summary of the most important resolutions adopted follows below.

Dividend
In accordance with the board’s proposal, the AGM resolved that no dividend is to be paid for the financial year 2019.

Election of the board of directors, auditor and resolutions on remuneration
Bert Junno, Jan Nilsson, Jonas Ekblom and Per Lundin were elected as new members of the board. Peter Nilsson was re-elected as a board member. Bert Junno was elected as the new chairman of the board of directors. It was resolved that remuneration will amount to  SEK 200,000 to the chairman of the board and SEK 125,000 to every other board member who do not receive any salary from the company.

MAZARS SET Revisionsbyrå AB was re-elected as the company’s auditor, with Anders O Persson as the principal auditor. The AGM resolved on remuneration according to approved invoices.

Discharge from liability
The AGM resolved to discharge the board of directors and the CEO from liability for the financial year 2019.

Resolution regarding amendment to the Articles of Association
The AGM resolved to amend the Articles of Association according to the table below.

Previous wording Resolved wording
1 § Registered name
The company’s registered name is CombiGene AB. The company is public (“publ”).
1 § Business name
The company’s business name is CombiGene AB. The company is public (“publ”).
3 § The object of the company’s business
The object of the company’s business is to develop and commercialize gene therapy for treatment of primarily neurological and psychiatric diseases as well as any other business compatible therewith.
3 § The object of the company’s business
The object of the company’s business is to develop and commercialize gene therapy for treatment of serious diseases that today lack adequate treatment methods as well as any other business compatible therewith.
4 § Share capital
The share capital shall be not less than SEK 5,000,000 and not more than SEK 20,000,000.
4 § Share capital
The share capital shall be not less than SEK 10,000,000 and not more than SEK 40,000,000.
5 § Number of shares
The number of shares in the company shall be not less than 50,000,000 and not more than 200,000,000.
5 § Number of shares
The number of shares in the company shall be not less than 100,000,000 and not more than 400,000,000.

 

Authorisation for the board of directors to resolve on new issues 0f shares, convertibles or warrants
The AGM resolved, in accordance with the proposed resolution in the notice to the AGM, to authorize the board of directors to, on one or more occasions before the next AGM, with or without pre-emption rights for the shareholders, resolve on new issues of shares as well as issues of warrants and/or convertibles.

Lund, 29 June 2020
CombiGene AB
The board of directors

 

 

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden

Linked In     Twitter      Facebook